Factors influencing the effect of age on prognosis in breast cancer: population based study

Abstract

Objective: To investigate whether young age at diagnosis is a negative prognostic factor in primary breast cancer and how stage of disease at diagnosis and treatment influences such an association.

Design: Retrospective cohort study based on a population based database of patients with breast cancer containing detailed information on tumour characteristics, treatment regimens, and survival.

Setting: Denmark.

Subjects: 10 356 women with primary breast cancer who were less than 50 years old at diagnosis.

Main outcome measures: Relative risk of dying within the first 10 years after diagnosis according to age at diagnosis after adjustment for known prognostic factors and expected mortality.

Results: Overall, young women with low risk disease who did not receive adjuvant treatment had a significantly increased risk of dying; risk increased with decreasing age at diagnosis (adjusted relative risk: 45-49 years (reference): 1; 40-44 years: 1.12 (95% confidence interval 0.89 to 1.40); 35-39 years: 1.40 (1.10 to 1.78); <35 years: 2.18 (1.64 to 2.89). However, no similar trend was seen in patients who received adjuvant cytotoxic treatment. The increased risk in younger women who did not receive adjuvant treatment compared with those who did remained when women were grouped according to presence of node negative disease and by tumour size.

Conclusion: The negative prognostic effect of young age is almost exclusively seen in women diagnosed with low risk disease who did not receive adjuvant cytotoxic treatment. These results suggest that young women with breast cancer, on the basis of age alone, should be regarded as high risk patients and be given adjuvant cytotoxic treatment.

Figures

Figure

Adjusted relative risk of dying after diagnosis of primary breast cancer according to age at diagnosis among 4329 low risk patients who received no adjuvant treatment (top) and 2824 high risk patients who received adjuvant cytotoxic treatment (bottom). Women aged 45-49 at diagnosis were used as reference. Bars indicate 95% confidence intervals. Relative risk was adjusted for tumour size, nodal status, histological grading, year of diagnosis, and expected mortality